The emergence and worldwide spread of the species Trichophyton indotineae causing difficult-to-treat dermatophytosis: A new challenge in the management of dermatophytosis.

Introduction

Superficial fungal infections of the skin, hair, and nails are the fourth most common cause of human disease affecting 20% to 25% of the world’s population [1]. Dermatophytosis is a superficial fungal infection caused by dermatophytic fungi that affect skin and the keratinized structures (hair and nails) arising from it. Dermatophytes, especially from the genera Trichophyton, cause the majority of superficial mycoses. These infections result in considerable morbidity and economic burden on the healthcare system [2]. In recent years, an alarming increase in the frequency of recalcitrant superficial fungal infections caused by novel species of Trichophyton, i.e., Trichophyton indotineae has been witnessed worldwide [3-24]. Importantly, the majority of the T. indotineae strains exhibit alteration in the squalene epoxidase (SQLE) gene that confers high terbinafine (TRB) resistance [3-5,7,10,11,13-17,19,21,22,25-28]. TRB is a first-line drug for treatment of moderate to severe dermatophytosis, and patients with T. indotineae infections typically show decreased effectiveness of oral therapy with this antifungal [29]. T. indotineae has been designated recently in the year 2020 as a distinct species independent of Trichophyton interdigitale and Trichophyton mentagrophytes on the basis of internal transcribed spacer (ITS) region sequencing of 2 highly TRB-resistant Trichophyton strains from a Nepali patient and an Indian patient [5]. On ITS phylogenetic analysis, TRB-resistant Indian strains cluster independently of the clusters of the T. interdigitale and T. mentagrophytes strains and differ in 2 to 3 single-nucleotide polymorphisms (SNPs) from T. mentagrophytes/T. interdigitale strains [5]. Subsequently, multigene polyphasic analysis of a larger data set of T. indotineae strains showed that these strains have distinct sequences of the high mobility group (HMG) gene as compared to T. mentagrophytes s. str. and T. interdigitale s. str [30]. Unlike the infections caused by T. mentagrophytes and T. interdigitale, T. indotineae often presents with extensive skin lesions and a chronic relapsing course. The whole genome sequencing analysis of 20 T. indotineae strains demonstrate that this new species is distinct clonal offshoot of T. mentagrophytes/T. interdigitale spp. complex. Thus, naming of this emerging antifungal-resistant species was essential as it could not be unambiguously identified as either T. mentagrophytes or T. interdigitale based on ITS sequencing, mycological and physiological characteristics.

In the last few years, dermatophytosis due to T. indotineae has not been limited to the Indian subcontinent but has also spread to Europe, Middle East, and North America related to travel and migration [7-24]. Further, reports of increasing treatment failure and acquisition of drug resistance in these difficult to treat T. indotineae infections have brought this entity to forefront due to limited alternative therapies. Although the significance of this problem has not gained global attention, it is just a matter of time when recalcitrant superficial dermatophytosis will be a potential public health threat worldwide. In this update, we apprise the emergence of T. indotineae in the Indian subcontinent and its rapid worldwide migration. Further, we highlight the challenges in the mycological identification and impact of the drug resistant T. indotineae strains on treatment of dermatophytosis.

A unique terbinafine-resistant Trichophyton species, T. indotineae, is causing alarming, difficult-to-treat dermatophytosis in India

The ongoing outbreak of dermatophytosis in India is characterized by extensive and difficult—to-treat chronic and chronic relapsing infection of the body (tinea corporis) and the groins (tinea cruris) (Fig 1) [31]. The possible underlying factors driving the outbreak of recalcitrant infections in India are multiple but not limited to over-the-counter availability and use of combination steroid–antifungal–antibiotic creams, suboptimal and irrational regimens of prescribed antifungals, and brands with low efficacy. In 2014 to 2017, highly TRB-resistant T. interdigitale strains causing tinea cruris and tinea corporis infections were identified in North India [3,4,25]. TRB is an allylamine antifungal used orally and topically as a first-line drug in the therapy of dermatophyte infections. TRB resistance has been predominantly attributed to point alterations in the SQLE target gene, a key enzyme in the ergosterol biosynthetic pathway leading to single amino acid substitutions. In 2018, Singh and colleagues reported that TRB-resistant T. interdigitale isolates from cases of tinea corporis/cruris in 3 hospitals in Delhi, India exhibited elevated minimum inhibitory concentrations (MICs range 1 to ≥32 mg/L) to TRB and had single amino acid substitutions Leu393Phe or Phe397Leu in the SQLE. Remarkably, a considerably high TRB resistance rate of 32% was recorded using CLSI broth microdilution method [3]. Further, whole genome sequence analysis of Trichophyton species causing severe superficial dermatophytosis in North India confirmed a unique Trichophyton strain related to an early diverging clade of the T. mentagrophytes/interdigitale complex. The study pointed out that a new population of Trichophyton with highly related isolates (42 SNPs difference between any 2 isolates) exhibiting high rates of in vitro antifungal resistance was driving an ongoing outbreak of dermatophytosis in India [4]. Followed by this report, in 2020, Japanese investigators Kano and colleagues identified these highly TRB-resistant T. interdigitale-like strains isolated from a Nepali patient and an Indian patient with tinea corporis in Japan as a new species, i.e., T. indotineae. The rDNA ITS region sequences of their study isolates were 100% identical to TRB-resistant strains of T. interdigitale, which were isolated in Delhi, India, and harbored alterations in SQLE. Similar to Indian strains, the isolates exhibited high MICs (32 mg/L) for TRB and contained an amino acid substitution (Phe397Leu) in SQLE. To avoid confusion in the taxonomy of the T. mentagrophytes/interdigitale complex, the highly TRB-resistant Indian strains were designated as a new species independent of T. interdigitale/T. mentagrophytes, according to clinical and mycological features [5].

Fig 1

Annular plaques with raised edges and scaly central region over groins (a) and buttocks (b). Note the prominent pigmentation, a common feature seen in T. indotineae infections in Indian patients.

Molecular identification of T. indotineae based on the internal transcribed spacer (ITS) region sequences

The identification of T. indotineae is challenging in the routine microbiology laboratories due to the marked morphological similarities of the species with T. mentagrophytes and T. interdigitale [5,30]. These species cannot be distinguished by phenotypic tests, although colony reverse of T. indotineae is most often pale-brown to yellow-orange in colour and isolates are less often positive in Tween-80 opacity, urea hydrolysis, and hair perforation tests than T. mentagrophytes and T. interdigitale [30]. In fact, in the last 5 years before labelling T. indotineae as a species de novo, studies based on rDNA ITS region sequencing identified Indian Trichophyton strains as T. mentagrophytes/interdigitale; further, Nenoff and colleagues grouped the strains as T. mentagrophytes Type VIII [3,4,6,26,32]. Currently, T. indotineae is unequivocally identified by the ITS sequences, which differ only at 2 and 3 nucleotide positions from ITS sequences of T. mentagrophytes and T. interdigitale, respectively. The BLAST searches of ITS sequences of T. indotineae on NCBI database still show ≥99% sequence similarity with T. mentagrophytes, T. interdigitale, and T. indotineae. Therefore, to obtain accurate identification (i.e., sequence similarity of 100% with T. indotineae), ITS sequences of well-defined reference strains described by Tang and colleagues [30], importantly, primary T. indotineae strains (NUBS19006 and NUBS19007), should be included in the analysis. Further, based on HMG gene sequences, T. indotineae can be differentiated from T. interdigitale and T. mentagrophytes, which differ at 4 and 1 nucleotide positions, respectively [30]. It is important to draw attention that incorrect nomenclature of several CBS reference and neotype strains of Trichophyton spp. in the public database results in misidentification warranting updating of the database [32].

Global spread of terbinafine-resistant T. indotineae strains

The spread of T. indotineae in Europe was noticed as early as in 2011 in Germany and most recently in 2019 to 2020, several cases have been reported from other European countries related to travel and migration [11-17,22,23,33]. Notably, 2 cases of tinea corporis and tinea cruris due to T. indotineae reported recently from Germany occurred in 2011 and 2013, even before the outbreak of dermatophytosis in India was recognised. Both the patients had travel links to India [12]. However, the strains had low TRB MICs and no SQLE alterations associated with TRB resistance was observed, suggesting that the early outbreak strains were probably not resistant to TRB. These findings correlate with absence of reports of TRB resistance until 2017 in India. Another report from Germany highlights that 29 patients with T. indotineae infections occurring during 2016 to 2020 had a history of travel to India, Pakistan, Bangladesh, Iraq, Bahrain, Libya, and other unspecified countries [15]. Notably, TRB-resistant T. indotineae strains isolated from cases in Germany, Denmark, and Switzerland during 2016 to 2020 exhibited Phe397Leu and Leu393Phe amino acid substitutions that confer resistance to TRB [11,15,22,33]. Since 2018, several cases of clinically resistant tinea corporis with extensive lesions that do not respond to TRB have been reported from France [13,14]. These patients were either recent immigrants or born in a country on the Indian subcontinent. The first case series of TRB-resistant T. indotineae infection in Canadian patients also emphasise travel or immigration from northern India as the source of T. indotineae [18]. The global reports of T. indotineae are listed in Table 1, which predominantly spread from 2016 onwards from the Indian subcontinent. Interestingly, Jabet and colleagues screened rDNA ITS sequences (in GenBank) of T. indotineae through March 2021 and observed widespread dissemination of the Indian strain with 12.8% of known sequences in the GenBank were from the Middle East and 9.6% from Europe. Remarkably, 98.8% of the sequences were of human origin and 6 sequences indicated an animal origin [13].

Table 1

Details of T. indotineae infections outside India.

Countries reporting T. indotineae: Year of publication	Year of collection of strains	T. indotineae strains/total number of Trichophyton spp. strains investigated	Travel history or patients origin	Patients age group; clinical details	Treatment and outcome	TRB MICs (mg/L) / substitution in SQLE gene	Azole MICs (mg/L)	References
East and South East Asia
Japan: 2020	2019	2/2	Nepal and India	27 and 47-years;tinea faciei/ corporis/ cruris	OralTRB→ITC/RVZ→ITRTopicalBFN, TRB, KTC, LUZOutcomeComplete cure with ITC and LUZ	>32 /Phe397Leu	ITC: 0.03CTZ: 0.06–4MCZ: 0.125–8LUZ: <0.03RVZ: 0.03–0.5	[5]
Vietnam: 2022	2020	1/1	Autochthonous	27 years; tinea corporis	OralITCTopicalKTCOutcomeComplete cure	0.25	ITC: 0.125VRC: 0.25	[8]
Cambodia: 2019	2019	1/4	NM	26 years; tinea corporis	NM	ND	ND	[9]
Middle East Asia
Iran: 2019	2016–2018*	116/1003*	Australia/ India/ Iran/Oman	NM; tinea corporis/ cruris/ faciei	NM	0.003- ≥32/ ND	ND	[20]
Iran: 2020	NM	4/4	Autochthonous	4–64 years; tinea corporis/ cruris/ pedis	OralFLU→ prednisolone+methotrexate→ TRB→ITC→VRC/ FLU→ITC→VRC/ TRB→ITCTopicalTRB, CTZ and SER.OutcomeComplete cure with oral VRC or ITC	≥8/Phe397Leu	ITC: ≥4FLU: ≥16VRC: 0.2–0.5PSZ: 0.06–0.313	[21]
Iran: 2020	2016–2018	28/141	Autochthonous	NM; tinea corporis/ cruris	NM	>32/Phe397Leu, Leu393Ser	ITC: 0.062–2EFN: 0.001–0.125CTZ: 0.5–32LUZ: 0.0004–0.015GRE: 0.25–4AMO: 0.125–4CPO: 0.062–1	[19]
Iraq: 2021	2016–2021	18/48	Autochthonous	4 months-70 years; tinea corporis/ faciei/ manuum/ capitis / pedis/ cruris/ unguium/ barbae	TopicalSteroidsOutcomelesions either enlarged or flared again	ND	ND	[24]
Iran: 2022	2018–2019	10/82	Autochthonous	11–60 years; tinea corporis/ cruris/ pedis/ capitis/ faciei/ manuum	NM	0.015–32/Phe397Leu	ITC 0.06–16FLU 0.125–16VRC 0.125–8KTC: 0.125–16PSZ: 0.125–16AMB: 0.125–16	[7]
Europe
Germany: 2020	2011–2020	5/5	Autochthonous/ India/Yemen	20–38 years; tinea corporis/ cruris/ manuum/ faciei	OralITC →TRB/Several cycle of TRB and ITCTopicalCTZ, CPO, TRB and MCZOutcomeMajority of patients experienced recurrence.	≤ 0.06	FLU: 16–64ITC: 0.03–0.06VRC: 0.125–0.5	[12]
Germany: 2019	2019	1/1	Bahrain	6 months; tinea corporis/ cruris	TopicalTRB→ MCZ and CPOOutcomeComplete cure with MCZ and CPO	>0.2/ Phe397Leu	ND	[10]
Germany: 2020	2016–2020	29/29	Autochthonous/ India/Pakistan/ Bangladesh/ Iraq/Bahrain/ Libya	6 months–58 years; tinea cruris/ corporis/ faciei/ manuum/ unguium/ pedis	Treatment mentioned for 4 patients only.OralFLU and TRB→ITCTopicalTRB, MCZ, CPO, CTZ, SEROutcomeComplete cure with oral ITC	0.2-16/Phe397Leu, Leu393Phe	ITC: 0.03–0.5VRC: 0.03–0.5	[15]
Switzerland: 2021	2009–2019	11/162	India/Bangladesh/ Thailand	31–41 years; tinea cruris/ corporis/ faciei/ pedis	OralTRB or ITC or FLUTopicalTRB, KTC, CLT, AMO, MCZ, ECZ, ISAOutcomeNo follow up	≥4/Phe397Leu	MIC values not mentioned	[22]
France: 2022	2017–2021	7/10	France/ India/ Bangladesh/ Myanmar	16–53 years; tinea cruris/ corporis	OralTRB/ TRB→GRE/ TRB→GRE→ITCTopicalTRB, ECZ, BFN, OMC, MCZ, CPOOutcomeTreatment failed in patients harbouring strains of TRB MICs 2->8 mg/L	0.06 ->8/Phe397Leu, Leu393Ser	ITC: 0.016–0.25VRC: 0.03–0.5AMO: 0.01–0.125	[13]
France: 2022	2018–2019	7/350	India/ Bangladesh/ Sri Lanka	20–57 years; tinea corporis/ cruris	OralTRB/ TRB→ITC/ TRB→GRE→ITC/ FLUTopicalBFN, CPO, TRBOutcomeCure with oral ITC and oral ITC with topical BFN	0.014-4/Phe397Leu, Leu393Ser	ITC: 015–16VRC: 0.125–2PSZ 0.03–0.5ISA: 0.125–4	[14]
Belgium: 2020	2018	1/182	Autochthonous	25 years; tinea cruris/corporis/capitis	OralTRBTopicalSulconazole nitrate and KTCOutcomeNo follow up	4/Phe397Leu	ITC: 0.016VRC: 0.5AMO: 0.06	[16]
Greece: 2019	2010–2019	9/112	Greece/Syria/Iran	9 months to 90 years; tinea cruris/corporis	OralTRB or ITC or FLUTopicalTRB and azole ointmentOutcomeImprovement with topical azoles and oral ITC	0.25-8/Phe397Leu, Leu393Ser	ITC: 0.016–0.125VRC: 0.03–0.5AMO: 0.125–0.25	[17]
Switzerland, Greece, Estonia, Finland: 2021	2020	11/96	India/Bangladesh/ Pakistan/The United Arab Emirates	NM; tinea/ corporis/ capitis	OralTRB→ ITC/ TRB→ FLU/ TRB→GREOutcomeNM	ND	ND	[23]
Denmark: 2022	2019–2020	7/63	Autochthonous	NM	NM	2- ≥4Phe397Leu, Leu393Phe	ITC: ≤ 0.016–0.06VRC: 0.06–0.5ISA: 0.06–0.5PSZ: 0.008–0.125OLO: 0.008–0.03	[11]
Denmark: 2019	2013–2018	1/14	Autochthonous	25 years; tinea cruris/corporis/faciei/ pedis	OralTRB/ TRB, ITC/ TRB, ITC, FLU/ TRB, ITC, GRE/ TRB, ITC, FLU, GRETopicalTRB, AMO, CPO, KTC and MCZ-hydrocortisone combinationOutcomeNM	≥4Phe397Leu	ND	[33]
North America
Canada: 2022	2021	8/8	India/Thailand	26–78 years; tinea cruris/corporis/faciei/ pedis	OralTRB/ TRB→FLU/ ITC/ ITC→ FLUTopicalTRB, KTC, CTZ, clobetasol, betamethasone, betamethasone dipropionate and fluocinonideOutcomeComplete cure with oral ITC in 1 patient	ND	ND	[18]

AMO, amorolfine; AMB, Amphotericin B; BFN, bifonazole; CPO, ciclopirox olamine; CTZ, clotrimazole; ECZ, econazole; EFN, efinaconazole; FLU, fluconazole; GRE, griseofulvin; ISA, isavuconazole; ITC, itraconazole; KTC, ketoconazole; LUZ, luliconazole; MCZ, miconazole; ND, not determined; NM, not mentioned; OLO, olorofim; OMC, omoconazole; PSZ, posaconazole; RVZ, ravuconazole; SER, sertaconazole; TRB, terbinafine; VRC, voriconazole.

*Out of 1,003, 397 were strains from patient samples (collected during 2016–2018) and the remaining were ITS (internal transcribed spacer) region sequences retrieved from GenBank.

→ denotes “followed by”.

Developments in the antifungal susceptibility testing (AFST) and mechanism of resistance in T. indotineae

AFST of dermatophytes is not routinely performed as both the reference CLSI and EUCAST methods are time consuming, and technical constraints related to slow growth and bacterial contamination remain a challenge [34,35]. The EUCAST method recommends chloramphenicol and cycloheximide supplemented growth media (to inhibit bacterial contamination) with a spectrophotometric endpoint reading using 50% growth inhibition [34]. EUCAST tentative epidemiological cutoff values (ECOFFS) for T. indotineae successfully demarcate isolates with and without SQLE resistance alterations [11]. No clinical breakpoints for TRB have been established by CLSI, and several reports have adopted variable MIC values (0.25 and ≥2 mg/L) for identification of TRB-resistant isolates. [3,4,15,26]. Further, for determination of MICs against azole drugs, variable criteria have been adopted by CLSI and EUCAST. For example, in itraconazole (ITC) testing, trailing growth may impact the observed resistance rate particularly when the MICs are determined using a stringent endpoint (90% inhibition) as adopted by CLSI in comparison with the 50% endpoint adopted by EUCAST [11,34,35]. The susceptibility testing by both the reference methods warrant further harmonization and standardization.

With the increasing number of resistant and recalcitrant T. indotineae cases, understanding the mechanism of resistance remains vital. In TRB-resistant Trichophyton species, alterations in the SQLE gene leading to amino acid substitutions at one of the 4 positions (Leu393, Phe397, Phe415, and His440) have been linked to resistance [36]. The most common substitution in T. indotineae strains reported worldwide is Phe397Leu in 95% of the studies leading to high TRB MICs (range: 1 to >32 mg/L) followed by Leu393Phe (MIC range: 1 to 64 mg/L) and Leu393Ser (MIC range: 0.5 to 1 mg/L) [3-5,7,10,11,13-17,19,21,22,25-28]. Notably, Phe397Leu or Leu393Phe substitutions confer high-level TRB resistance in T. mentagrophytes, T. interdigitale, T. indotineae, and T. rubrum [37]. Yamada and colleagues introduced the 2 common abovementioned amino acid substitutions into the endogenous SQLE gene of a TRB-sensitive Arthroderma vanbreuseghemii (formerly T. mentagrophytes) strain and showed that resistance to TRB in A. vanbreuseghemii transformants was due to the respective point alterations [36]. A newly developed DermaGenius Resistance real-time PCR assay is found to be highly efficacious in differentiation of SQLE wild type (T. indotineae susceptible) from mutant genotypes harbouring Phe397Leu or Leu393Phe substitution. However, the significance and clinical utility of such assays in patient management needs to be investigated [38]. Importantly, azole resistance in T. indotineae has been observed in one-third of reports from India and Europe [3,4,12,14,25-27]. T. indotineae strains with the double substitutions in the SQLE gene, i.e., Phe397Leu and Ala448Thr, exhibit increased MIC values of fluconazole, ITC, and voriconazole (VRC) [27]. However, the speculation that these double mutants lead to FLU, ITC, and VRC resistance in T. indotineae need to be experimentally investigated. A recent study highlighted that azole resistance in T. indotineae is due to overexpression of the TinCYP51B gene encoding sterol 14α-demethylases enzyme [39].

Multidrug-resistant T. indotineae and its impact on the treatment of dermatophytosis

TRB resistance rates ranging 17% to 75% and varying levels of ITC resistance up to 25% have been reported in T. indotineae strains from India [3,25,26]. In addition, several studies have reported high in vitro MIC values of VRC (range: 2 to >16 mg/L) and griseofulvin (range: 4 to 128 mg/L) [3,4,26]. It is important to emphasise that the treatment options for dermatophytosis are restricted and resistance to existing antifungals leaves no options for clinicians to treat severe persistent skin infections [40]. ITC remains the most effective antifungal for dermatophyte infections, with rising resistance to TRB. However, oral formulations of ITC have erratic absorption patterns leading to wide fluctuations in its serum concentrations. Although, monitoring of serum levels of ITC as in systemic mycoses is important for effective treatment outcome [41,42]. However, the high cost burden associated with regular therapeutic drug monitoring for this extremely prevalent infection, especially in lower-middle countries, is not practical. A single centre-based study reported that higher doses and longer durations of TRB therapy could overcome treatment failure associated with TRB-resistant strains [29]. Thus, appropriate dosage of TRB in treatment of dermatophytosis could prevent the usage of azole drugs and development of resistance against azole-based antifungal drugs. Recently, in vitro synergistic interactions with varying combinations of ITC, TRB, ketoconazole, and luliconazole (LUZ) have been observed in TRB-resistant Indian strains [43,44]. However, effectiveness of TRB and ITC in combination for treatment of tinea infections in a recent randomised trial showed no added beneficial effect over treatment with ITC alone [45]. Thus, combination treatment consisting of 2 systemic antifungals has no proven clinical benefit and must be avoided as it not only adds to cost of treatment, but also exposes patients to a greater array of adverse effects. It is more useful and rationale instead to combine oral drugs with topical antifungals with high susceptibility against the prevalent strain (e.g., LUZ) especially as topical antifungals achieve much higher levels in the skin. However, extensive skin involvement, as often seen with T. indotineae, makes the option economically unfeasible in many patients. Therefore, it’s important to develop newer highly potent antifungals for oral use and also gear up the clinical application of drugs like olorofim, which have high potent in vitro activity against T. indotineae [3,4,46,47]. Finally, T. indotineae has become widespread due to travel, immigration, and subsequent local transmission in the countries warranting urgent collective efforts at the global level to prevent its further dissemination.